IP Library Granted Patent US 8,263,082
Granted Patent B2
US 8,263,082 · App. 12/685,257 · Granted Sep 11, 2012

Chemically programmable immunity

Assignee: Altermune Technologies LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,082
App. No.
12/685,257
Granted
Sep 11, 2012
Kind
B2
Abstract

Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.

Claims (32)

1. A method of increasing a humoral immune response to a target in an individual comprising,

administering to the individual an effective amount of a composition comprising one or more immunity linkers,

wherein the linkers comprise at least one first binding site and at least one second binding site,

wherein the first binding site binds to any humoral immune response component of a pre-existing immune response,

wherein the second binding site binds to the target, and

wherein the target normally elicits a cellular immune response in the individual.

2. The method of claim 1 , wherein the target is a cancer cell or viral infected cell.

3. The method of claim 1 , wherein the target is a cancer cell.

4. The method of claim 1 , wherein the at least once second binding site is an aptamer nucleic acid.

5. The method of claim 1 , wherein the one or more immunity linkers comprise, two or more first binding sites that differ in

a) specificity for different sub-structures on the immune response component, or

b) affinity for the same sub-structures on the immune response component.

6. The method of claim 1 , wherein the at least one second binding site comprises an antibody or a fragment thereof.

7. The method of claim 1 , wherein the one or more immunity linkers comprise two or more second binding site that differ in

a) specificity for different epitopes on the target, or

b) affinity for the same epitope on the target.

8. A method of tuning or tailoring a humoral or innate immune response to a target in an individual comprising,

administering to the individual an effective amount of a composition comprising one or more immunity linkers,

wherein the linkers comprise at least one first binding site that binds to any humoral or innate immune response component of a pre-existing immune response,

further comprising at least one second binding site that binds to the target, and wherein the target normally elicits a cellular immune response in the individual.

9. The method of claim 8 , wherein the target is a pathogen.

10. The method of claim 8 , wherein the target is an altered cell.

11. The method of claim 10 , wherein the altered cell is a cancer or viral infected cell.

12. The method of claim 8 , wherein the at least one second binding site comprises an aptamer nucleic acid.

13. The method of claim 8 , wherein the at least one second binding site comprises an antibody or a fragment thereof.

14. The method of claim 8 , wherein the one or more immunity linkers comprise two or more first binding site that differ in

a) specificity for different sub-structures on the immune response component, or

b) affinity for the same sub-structures on the immune response component.

15. The method of claim 14 , wherein the immune response component comprises an antibody.

16. The method of claim 8 , wherein the one or more immunity linkers comprise two or more second binding site that differ in

a) specificity for different epitopes on the target, or

b) affinity for the same epitope on the target.

Assignments (3)
CHANGE OF NAME Recorded Apr 2, 2019
From: ALTERMUNE LIMITED
To: CENTAURI THERAPEUTICS LIMITED
Reel/Frame 048775/0631 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2010
From: ALTERMUNE LLC
To: ALTERMUNE TECHNOLOGIES LLC
Reel/Frame 024864/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2010
From: MULLIS, KARY B.
To: ALTERMUNE LLC
Reel/Frame 024866/0699 →
Continuity (6)
Continuation 10754456 · Jan 9, 2004
Continuation In Part 10696770 · Oct 29, 2003
Continuation In Part 10178046 · Jun 21, 2002
Continuation PCTUS0035179 · Dec 21, 2000
Provisional Application 60171707 · Dec 22, 1999
Related Publication 20100247535A1 · Sep 30, 2010